NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle

The Sydney Morning Herald - Oct 13, 2026

NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.

Read full article
More News
Business Vantage Views

Business Vantage Views is a dedicated online news network that brings to you the latest state of business and finance so that you can make the best judgment on investment and future planning.